{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:15:41Z","timestamp":1789038941025,"version":"build-2803163510"},"reference-count":29,"publisher":"Korean Cancer Association","issue":"4","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"name":"A.Menarini Korea"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2025,10,15]]},"abstract":"<jats:p>Purpose Fentanyl, a highly lipophilic opioid, was developed as a sublingual fentanyl tablet (SFT) for the management of breakthrough cancer pain (BTcP), and its efficacy and safety were confirmed in a randomized, controlled study. We investigated the effectiveness and safety of SFT administered to alleviate BTcP in a real-world setting.Materials and Methods In this prospective, open, single-cohort study, conducted in 13 referral hospitals in South Korea, opioid-tolerant cancer patients receiving around-the-clock opioids for persistent cancer pain were enrolled if the individual had BTcP \u2265 1 episode\/day during the preceding week. The primary outcome was the SFT titration success rate.Results Among 113 patients evaluated for effectiveness, 103 patients (91.2%) had a successful titration of SFT, with an effective dose range between 100 \u03bcg and 400 \u03bcg. The most frequent dose was 100 \u03bcg, administered to 65.0%, 72.1%, and 81.8% of the patients at week 1, 4, and 12, respectively. The proportion of patients achieving the personalized pain goal assessed in the first week was 75.2%. The mean change in pain intensity measured with a numeric rating scale at 30 and 60 minutes after taking SFT was \u20132.57 and \u20133.62, respectively (p &lt; 0.001 for both). The incidence rate of adverse events related to SFT among 133 patients included for safety evaluation was 9.0% (12\/133), which included vomiting (3.0%), nausea (2.3%), and headache (1.5%).Conclusion In a real-world setting, SFT provides rapid and effective analgesia in BTcP, even at the lowest dose (100 \u03bcg), and the safety profile was acceptable.<\/jats:p>","DOI":"10.4143\/crt.2024.557","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T20:22:26Z","timestamp":1735158146000},"page":"1231-1239","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients"],"prefix":"10.4143","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2406-5848","authenticated-orcid":true,"given":"Youn Seon","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-8036","authenticated-orcid":true,"given":"Su-Jin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Kyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Byung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaewon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kee","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyung Bok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Suk","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MinYoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-6730","authenticated-orcid":true,"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90004-w"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.12.009"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.02.035"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-016-1490-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2017-001467"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.03.025"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.02.015"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2015.087"},{"key":"ref9","first-page":"559","volume-title":"Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options","author":"Mercadante","year":"2015"},{"key":"ref10","first-page":"17701","volume-title":"Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study","author":"Perez-Hernandez","year":"2019"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1191\/0269216304pm890oa"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/jpr.s135807"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2014.0209"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/spc.0000000000000494"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.8.611"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210932.27945.4a"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp541"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02264.x"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903368310"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.545380"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00525.x"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/md9.0000000000000088"},{"key":"ref23","first-page":"e11593","volume-title":"Proportional dose of rapid-onset opioid in breakthrough cancer pain management: an open-label, multicenter study","author":"Yen","year":"2018"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1179"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.07.006"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s0304-3959(98)00179-1"},{"key":"ref27","first-page":"1177","volume-title":"Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period","author":"Kress","year":"2009"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2015-0009"},{"key":"ref29","first-page":"9","volume-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","author":"Dworkin","year":"2005"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-557.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.557","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-557.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:03:50Z","timestamp":1760486630000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2024.557","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"2024-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}